OnKure Therapeutics (OKUR) director awarded 22,350 stock options at $4.14 strike
Rhea-AI Filing Summary
OnKure Therapeutics, Inc. reported that director R Michael Carruthers received a grant of stock options covering 22,350 shares of Class A common stock on August 7, 2026. The options have an exercise price of $4.14 per share, expire on August 6, 2036, and will vest 100% on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Carruthers R Michael
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 22,350 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 22,350 shares (Direct)
Footnotes (1)
- F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.
Key Figures
Options granted: 22,350 shares
Exercise price: $4.14 per share
Expiration date: August 6, 2036
+2 more
5 metrics
Options granted
22,350 shares
Stock option grant to director on August 7, 2026
Exercise price
$4.14 per share
Exercise price of stock options granted
Expiration date
August 6, 2036
Option expiration for the granted stock options
Vesting date trigger
June 4, 2027
100% vesting on earlier of June 4, 2027 or day before next annual meeting
Underlying shares
22,350 shares
Class A common stock underlying the stock options
Key Terms
Stock Option (right to buy), exercise price, vesting, annual meeting of stockholders
4 terms
Stock Option (right to buy) financial
"security_title is listed as Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price is reported as the exercise price of $4.14"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the shares subject to the option will vest on the earlier of June 4, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders"
FAQ
What did OnKure Therapeutics (OKUR) disclose about insider R Michael Carruthers?
OnKure Therapeutics disclosed that director R Michael Carruthers received a stock option grant for 22,350 shares. The options relate to Class A common stock and were awarded as a compensation grant on August 7, 2026.
How many options were granted to R Michael Carruthers at OnKure Therapeutics (OKUR)?
R Michael Carruthers was granted 22,350 stock options at OnKure Therapeutics. Each option is exercisable for one share of Class A common stock, subject to the vesting conditions described in the grant footnote.
What is the exercise price of the options granted to the OnKure (OKUR) director?
The options granted to the OnKure director have an exercise price of $4.14 per share. This means each option allows the purchase of one share of Class A common stock at $4.14, once the options are vested and exercisable.
When do the newly granted OnKure Therapeutics (OKUR) options vest?
The options will vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual meeting of stockholders. Vesting is contingent on R Michael Carruthers continuing as a service provider through the applicable vesting date.
What is the expiration date of the stock options granted at OnKure Therapeutics (OKUR)?
The stock options granted to R Michael Carruthers expire on August 6, 2036. After that expiration date, any unexercised options will no longer be exercisable for shares of Class A common stock.
Is the OnKure Therapeutics (OKUR) Form 4 transaction a purchase or a grant?
The Form 4 transaction is reported as a grant or award acquisition of stock options, coded as transaction type A. It reflects a compensation-related award, not an open-market purchase or sale of existing shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
